SCHEMBL19989099

SCHEMBL19989099

Cc1cc(S(=O)(=O)N2CCC(O)(C(F)(F)F)C2)ccc1Br

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.46
RIN1 Q13671 1/20 0.46
ALDH1A1 P00352 5/20 0.45
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
LMNA P02545 3/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
PKM P14618 1/20 0.40
GAA P10253 2/20 0.40
TSHR P16473 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NEK2 P51955 1/20 0.38
HSD11B1 P28845 2/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
YAP1 P46937 1/20 0.36
TEAD4 Q15561 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29859203 1.00 ABL1 (0.46) ABL1RIN1ALDH1A1MEN1KMT2A
SCHEMBL29498495 0.90 ABL1 (0.46) ABL1RIN1ALDH1A1MEN1KMT2A
SCHEMBL19994863 0.90 ABL1 (0.46) ABL1RIN1ALDH1A1MEN1KMT2A
SCHEMBL19989556 0.84 ALDH1A1 (0.50) ABL1RIN1ALDH1A1MEN1KMT2A
SCHEMBL29859265 0.84 ALDH1A1 (0.50) ABL1RIN1ALDH1A1MEN1KMT2A
SCHEMBL18065581 0.82 ALDH1A1 (0.43) ALDH1A1LMNATSHRNEK2HSD11B1
SCHEMBL18065579 0.82 ALDH1A1 (0.43) ALDH1A1LMNATSHRNEK2HSD11B1
SCHEMBL19989141 0.81 ALDH1A1 (0.50) ABL1RIN1ALDH1A1MEN1KMT2A
SCHEMBL29859307 0.81 ALDH1A1 (0.50) ABL1RIN1ALDH1A1MEN1KMT2A
SCHEMBL19989512 0.78 ALDH1A1 (0.52) ABL1RIN1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109715608-B Indazole compounds for use in tendon and/or ligament injuries 诺华股份有限公司 2022-08-05 CN disclosed
EP-3515894-B1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2021-04-07 EP disclosed
EP-3515894-A1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES Novartis AG (CH) 2019-07-31 EP disclosed
US-10112907-B2 Substituted indazoles for treating tendon and/or ligament injuries NOVARTIS AG (CH) 2018-10-30 US disclosed
US-20180086716-A1 Indazole Compounds for Use in Tendon and/or Ligament Injuries NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2018-03-29 US disclosed
WO-2018055550-A1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10112907-B2 Substituted indazoles for treating tendon and/or ligament injuries SLC10A2, MMP1, TNNI3 ABL1 692/4885RIN1 3867/4885ALDH1A1 442/4885
US-20180086716-A1 Indazole Compounds for Use in Tendon and/or Ligament Injuries MMP1, SLC10A2, TNNI3 ABL1 1179/4885RIN1 3481/4885ALDH1A1 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.